Mutations associated with lamivudine-resistance in therapy-naive hepatitis B virus (HBV) infected patients with and without HIV co-infection: Implications for antiretroviral therapy in HBV and HIV co-infected south African patients

被引:44
作者
Selabe, S. Gloria
Lukhwareni, Azwidowi
Song, Ernest
Leeuw, Yeegan G. M.
Burnett, Rosemary J.
Mphahlele, M. Jeffrey
机构
[1] Univ Limpopo, Dept Virol, HIV & Hepatitis Res Unit, Pretoria, South Africa
[2] Johannesburg Hosp, Hepatol Div, Dept Med, Johannesburg, South Africa
[3] Univ Witwatersrand, Johannesburg, South Africa
[4] Margarita Hlth Ctr, Pretoria, South Africa
关键词
lamivudine-resistant HBV strains; hepatitis B virus; human immunodeficiency virus; HBV-HIV coinfection; sub-Saharan Africa;
D O I
10.1002/jmv.20974
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
This was an exploratory study to investigate larnivudine-resistant hepatitis 13 virus (HBV) strains in selected lamivudine-naive HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients. Thirty-five lamivudine-naive HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HlV co-infected patients. The latter group was further sub-divided into 13 occult HBV (HBsAg-negative) and 7 overt HBV (HBsAg-positive) patients. HBsAg, anti-HBs, anti-HBc, and anti-HIV 1/2 were determined as part of routine diagnosis using Axsym assays (Abbott Laboratories, North Chicago, IL). Serum samples were PCR amplified with HBV reverse transcriptase (RT) primers, followed by direct sequencing across the tyrosine-methionine-aspartate-aspartate (YMDD) motif of the major catalytic region in the C domain of the HBV RT enzyme. HBV viral load was performed with Amplicor HBV Monitor((R)) test v2.0 (Roche Diagnostics, Penzberg, Germany). HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 HBV-HIV co-infected patients. To the best of our knowledge, this constitutes the first report of HBV lamivudine-resistant strains in therapy-naive HBV-HIV co-infected patients. The HBV viral loads for mono-infected and co-infected patients ranged from 3.32 x 10(2) to 3.82 x 10(7) and < 200 to 4.40 x 10(3) copies/ml, respectively. It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of HBV-HIV co-infected patients.
引用
收藏
页码:1650 / 1654
页数:5
相关论文
共 50 条
  • [31] Impact of Highly Active Antiretroviral Therapy on Hepatitis C Virus Protease Quasispecies Diversity in HIV Co-Infected Patients
    Winters, Mark A.
    Chary, Aarthi
    Eison, Robert
    Asmuth, David
    Holodniy, Mark
    JOURNAL OF MEDICAL VIROLOGY, 2010, 82 (05) : 791 - 798
  • [32] HIV/HBV co-infection and rate of antiretroviral treatment change after highly active antiretroviral treatment initiation in a cohort of HIV-infected patients in Greece
    Nikolopoulos, G. K.
    Paraskevis, D.
    Hatzitheodorou, E.
    Moschidis, Z.
    Sypsa, V.
    Zavitsanos, X.
    Kalapothaki, V.
    Hatzakis, A.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2010, 21 (10) : 702 - 707
  • [33] Hepatitis B Virus (HBV) Genotype Mixtures, Viral Load, and Liver Damage in HBV Patients Co-infected With Human Immunodeficiency Virus
    Jose-Abrego, Alexis
    Roman, Sonia
    Rebello Pinho, Joao Renato
    de Castro, Vanessa Fusco Duarte
    Panduro, Arturo
    FRONTIERS IN MICROBIOLOGY, 2021, 12
  • [34] Development of Chronic Hepatitis B Virus Infection in Hepatitis B Surface Antigen Negative HIV/HBV Co-Infected Adults: A Rare Opportunistic Illness
    Landrum, Michael L.
    Roediger, Mollie P.
    Fieberg, Ann M.
    Weintrob, Amy C.
    Okulicz, Jason F.
    Crum-Cianflone, Nancy F.
    Ganesan, Anuradha
    Lalani, Tahaniyat
    Macalino, Grace E.
    Chun, Helen M.
    JOURNAL OF MEDICAL VIROLOGY, 2011, 83 (09) : 1537 - 1543
  • [35] Tenofovir-based combination therapy for HIV/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia
    Childs, Kate
    Joshi, Deepak
    Byrne, Ruth
    Bruce, Matthew
    Carey, Ivana
    Agarwal, Kosh
    Taylor, Chris
    AIDS, 2013, 27 (09) : 1443 - 1448
  • [36] Molecular Characterization of HBV Strains Circulating among the Treatment-Naive HIV/HBV Co-Infected Patients of Eastern India
    Saha, Debraj
    Pal, Ananya
    Biswas, Avik
    Panigrahi, Rajesh
    Sarkar, Neelakshi
    Das, Dipanwita
    Sarkar, Jayeeta
    Guha, Subhasish Kamal
    Saha, Bibhuti
    Chakrabarti, Sekhar
    Chakravarty, Runu
    PLOS ONE, 2014, 9 (02):
  • [37] Hepatitis B Virus Drug Resistance in HIV-1-Infected Patients Taking Lamivudine-Containing Antiretroviral Therapy
    Wongprasit, Pawinee
    Manosuthi, Weerawat
    Kiertiburanakul, Sasisopin
    Sungkanuparph, Somnuek
    AIDS PATIENT CARE AND STDS, 2010, 24 (04) : 205 - 209
  • [38] Naturally occurring antiviral drug resistance in HIV patients who are mono-infected or co-infected with HBV or HCV in China
    Deng, Haohui
    Deng, Xizi
    Liu, Yu
    Xu, Ying
    Lan, Yun
    Gao, Ming
    Xu, Min
    Gao, Hongbo
    Wu, Xiexing
    Liao, Baolin
    Chen, Weilie
    Zhao, Miaoxian
    Hu, Fengyu
    Wang, Zhanhui
    JOURNAL OF MEDICAL VIROLOGY, 2018, 90 (07) : 1246 - 1256
  • [39] Five-Year Review of HIV-Hepatitis B Virus (HBV) Co-Infected Patients in a New York City AIDS Center
    Kim, Jong Hun
    Psevdos, George, Jr.
    Sharp, Victoria
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2012, 27 (07) : 830 - 833
  • [40] Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database
    Petoumenos, K
    Ringland, C
    HIV MEDICINE, 2005, 6 (03) : 155 - 163